对CAR-T细胞疗法的瘤相关的细胞外矩阵障碍:克服治疗方法
Ilya Klabukov1,2,3,4, Alexander E Kabakov1,2, Anna Yakimova1,2
1National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia.
Current oncology (Toronto, Ont.)
|February 25, 2025
概括
化学抗原受体 (CAR) -T细胞疗法在固体瘤中面临挑战,原因是细胞外基质 (ECM). 本综述探讨了ECM如何阻碍CAR-T细胞功能,并讨论了克服这些障碍以改善癌症治疗的策略.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 生物医学工程 生物医学工程
背景情况:
- 化学抗原受体 (CAR) -T细胞疗法对血液癌症有效.
- 用CAR-T细胞治疗固体瘤受到瘤微环境,特别是细胞外基质 (ECM) 的限制.
研究的目的:
- 审查与瘤相关的ECM在限制固体瘤中CAR-T细胞治疗疗效方面的多方面的作用.
- 分析ECM如何阻碍CAR-T细胞透,生存和功能.
- 突出在CAR-T细胞治疗中克服ECM相关障碍的策略.
主要方法:
- 对研究CAR-T细胞疗法和瘤相关ECM的文献综述.
- 分析ECM的物理和免疫抑制作用.
- 识别新兴的治疗策略.
主要成果:
- 与瘤相关的ECM充当物理屏障,阻碍CAR-T细胞的透和迁移.
- 此外,ECM还起到免疫抑制因素的作用,影响CAR-T细胞的抗瘤活动.
- 工程CAR-T细胞和组合疗法在克服ECM障碍方面表现有前途.
结论:
- 与瘤相关的ECM在固体瘤中对CAR-T细胞疗法提出了重大挑战.
- 设计CAR-T细胞或结合疗法的策略可以减轻ECM相关的障碍.
- 通过解决ECM相互作用,进一步的研究可以优化CAR-T细胞疗法用于固体瘤治疗.
关键词:
在CAR-T细胞疗法中.底层膜的底层膜.癌症 癌症 癌症 癌症 癌症仿制性抗原受体的复制性受体.细胞外矩阵是细胞外矩阵.纤维化 纤维化基因工程是基因工程.淋巴细胞淋巴细胞.在一个comatrix上.固体瘤是一种固体瘤.瘤微环境是一个微环境.更多相关视频
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
418
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
相关概念视频
Tumor Immunotherapy
462
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
462
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
